Literature DB >> 33283221

Metabolic Syndrome and Cognitive Function in Midlife.

Janelle T Foret1, Stephanie Oleson2, Brennan Hickson3, Stephanie Valek4, Hirofumi Tanaka3, Andreana P Haley1,5.   

Abstract

OBJECTIVE: Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors associated with cognitive decline. We investigated the relationship between MetS and cognition in middle-aged adults. We hypothesized that higher numbers of MetS components will relate to poorer performance on executive function (EF) tasks as frontal lobe regions critical to EF are particularly vulnerable to cardiovascular disease.
METHODS: 197 adults (ages 40-60) participated. MetS was evaluated using established criteria. Composite scores for cognitive domains were computed as follows: Global cognitive function (subtests from the Wechsler Abbreviated Scale of Intelligence, 2nd Edition), EF (Stroop Color Word, Digit Span Backward, and Trails A and B), and memory (California Verbal Learning Test, 2 Edition).
RESULTS: Higher number of MetS components was related to weaker EF-F(4, 191) = 3.94, p = .004, MetS components ß = -.14, p = .044. A similar relationship was detected for tests of memory-F(4, 192) = 7.86, p < .001, MetS components ß = -.15, p = .032. Diagnosis of MetS was not significantly associated with EF domain score (ß = -.05, p = .506) but was significantly associated with memory scores-F(4, 189) = 8.81, p < .001, MetS diagnosis ß = -.19, p = .006.
CONCLUSIONS: Our findings support prior research linking MetS components at midlife to executive dysfunction and demonstrate that MetS, and its components are also associated with poorer memory function. This suggests that cognitive vulnerability can be detected at midlife. Interventions for MetS at midlife could alter cognitive outcomes.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Aging; Brain; Cognitive impairment; Executive function; Metabolic syndrome; Neuropsychological assessment

Year:  2020        PMID: 33283221     DOI: 10.1093/arclin/acaa112

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  5 in total

1.  Increased pulse wave velocity is related to impaired working memory and executive function in older adults with metabolic syndrome.

Authors:  Jigar Gosalia; Polly S Montgomery; Shangming Zhang; William A Pomilla; Ming Wang; Menglu Liang; Anna Csiszar; Zoltan Ungvari; Andriy Yabluchanskiy; David N Proctor; Andrew W Gardner
Journal:  Geroscience       Date:  2022-08-18       Impact factor: 7.581

2.  The Association Between Diet and Cardio-Metabolic Risk on Cognitive Performance: A Cross-Sectional Study of Middle-Aged Australian Adults.

Authors:  Sarah Gauci; Lauren M Young; Lizanne Arnoldy; Andrew Scholey; David J White; Annie-Claude Lassemillante; Denny Meyer; Andrew Pipingas
Journal:  Front Nutr       Date:  2022-04-28

3.  Modifying pathways by age and sex for the association between combined sleep disordered breathing and long sleep duration with neurocognitive decline in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

Authors:  Sonya S Kaur; Wassim Tarraf; Benson Wu; Kevin A Gonzalez; Martha Daviglus; Neomi Shah; Daniela Sotres-Alvarez; Linda C Gallo; William Wohlgemuth; Susan Redline; Hector M Gonzalez; Alberto R Ramos
Journal:  Alzheimers Dement       Date:  2021-05-25       Impact factor: 16.655

4.  The Metabolic Syndrome Is Associated With Lower Cognitive Performance and Reduced White Matter Integrity in Midlife: The CARDIA Study.

Authors:  Christina S Dintica; Tina Hoang; Norrina Allen; Stephen Sidney; Kristine Yaffe
Journal:  Front Neurosci       Date:  2022-07-18       Impact factor: 5.152

5.  Network Modeling Sex Differences in Brain Integrity and Metabolic Health.

Authors:  Janelle T Foret; Maria Dekhtyar; James H Cole; Drew D Gourley; Marie Caillaud; Hirofumi Tanaka; Andreana P Haley
Journal:  Front Aging Neurosci       Date:  2021-06-29       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.